CYTR - CYTR STOCK NEWS

CytRx Corporation (OTCQB: CYTR) will hold a town hall for stockholders on January 20, 2022, at 4:30 PM Eastern. The event will be led by new CEO Dr. Stephen Snowdy and will include a question-and-answer session. Access to the town hall will be provided here. Following the event, a recording will be available on the company's website.

CytRx Corporation (OTCQB: CYTR) announced that CFO John Caloz will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13. The presentation will highlight CytRx's promising pipeline, including licensing agreements with ImmunityBio and Orphazyme, as well as the Centurion BioPharma subsidiary and its innovative LADR™ Platform designed to enhance drug efficacy in solid tumors while reducing toxicity. View the presentation on CytRx's website post-conference.

CytRx Corporation (OTCQB:CYTR) announced that Dr. Stephen Snowdy has been appointed as the new CEO, effective January 10, 2022. He succeeds Steven A. Kriegsman, who stepped down from the role and also as Chairman of the Board, a position now held by Dr. Louis Ignarro. Dr. Snowdy brings over two decades of experience in life science investing and executive management, previously leading Visioneering Technologies, Inc. and Abby Med LLC. Both Kriegsman and Ignarro expressed confidence in Snowdy's vision to enhance value for shareholders and continue CytRx's focus on oncology and neurodegenerative diseases.

CytRx Corporation (OTCQB:CYTR) has highlighted recent clinical developments from ImmunityBio, Inc. (NASDAQ:IBRX) concerning the cancer treatment aldoxorubicin. ImmunityBio's QUILT 88 study has shown promising results in patients with metastatic pancreatic cancer, with 90% exceeding historical survival rates. Furthermore, CytRx has the potential for up to $343 million in milestone payments and royalties from its collaboration with ImmunityBio. Aldoxorubicin is also being evaluated for triple-negative breast cancer, head and neck cancer, and glioblastoma.

CytRx Corporation (OTCQB: CYTR) has announced plans for a world-class cancer center in Las Vegas, aiming to raise over $100 million through tax-deductible contributions. The center, a 501(C)3 not-for-profit entity, will support Centurion BioPharma in advancing its LADR™ oncology drug candidates. Recent successes include a Phase 2 trial for a combination immunotherapy for pancreatic cancer. The project aims to enhance cancer treatment options and establish Las Vegas as a medical tourism hub.

CytRx Corporation (OTCQB:CYTR) reported its Q3 2021 results, ending on September 30 with approximately $16.5 million in cash and a net loss of $1.7 million, an improvement from a $2.8 million loss in Q3 2020. General and administrative expenses decreased to $1.5 million from $2.2 million year-over-year. The company paid $165,000 as part of a $10 million securities purchase agreement. CytRx continues to explore strategic partnerships for clinical testing while supporting ImmunityBio's Phase 2 pancreatic cancer trial and Orphazyme's regulatory pursuits regarding arimoclomol.

CytRx Corporation has announced that its subsidiary, Centurion BioPharma, will present plans for a state-of-the-art cancer treatment center in Las Vegas, Nevada, on November 18, 2021. Executive Chairman Steven A. Kriegsman will address the Office of the Governor and the Las Vegas Global Economic Alliance at the event. The proposed center aims to become a premier hub for cancer treatment and medical tourism, addressing Nevada's historical struggles with cancer. The project has received support from local stakeholders.

Orphazyme has received encouraging feedback from the FDA following a Type A meeting regarding arimoclomol, a treatment for Niemann-Pick disease Type C (NPC). The FDA suggests that Orphazyme provide supplementary data and analyses to support its resubmission path after a previous Complete Response Letter indicated the need for more evidence regarding the drug’s efficacy. CytRx Corporation, which sold arimoclomol to Orphazyme, expressed optimism about the FDA’s invitation for further discussions and potential regulatory pathways.

CytRx Corporation highlights the early efficacy of its licensed drug aldoxorubicin in ImmunityBio's Phase 2 trial for advanced pancreatic cancer. The trial shows that 90% of evaluable patients exceeded historical survival rates, with 87% of those with extremely advanced disease also surpassing these rates. Mature data is expected in Q1 2022, and ImmunityBio is expanding enrollment due to positive early results. CytRx has potential milestone payments of up to $343 million from ImmunityBio for aldoxorubicin.